Generic name
Sodium bicarbonate, sodium chloride: adverse event reports filed with FDA
675 reports list it as a suspect or interacting product, 2018–2026. Class: Osmotic laxative.
- 675
- reports as suspect product
- 0% of all reports · about 84 a year
- 29
- reports, 12 months to June 2026
- 74 in the 12 months before
- 100%
- marked serious by the reporter
- 54.5% across the class
- 0.1%
- record death among outcomes, as reported
- 1 reports · not verified by FDA
675 adverse event reports received by FDA list sodium bicarbonate, sodium chloride, a generic name as a suspect or interacting product, from July 2018 to May 2026. A further 258 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 29 reports listed it, down 61% from 74 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 84 reports a year and 0% of the 20,646,523 reports in the database, and 0.5% of the reports for the osmotic laxative class. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are drug ineffective (57.3%), macular degeneration (54.5%) and therapeutic product effect incomplete (47.3%). A report can list several reactions, so shares add to more than 100%; 189 different terms appear across these reports. Drug ineffective is recorded in 57.3% of these reports, a larger share than in the median osmotic laxative drug (9.3%).
100% of the reports are marked serious by the reporter (54.5% across the class); 0.1% record death among the outcomes and 65.5% record hospitalisation, as reported. 51% of the reports came from other health professionals, and the largest patient age group is 65 to 74 (32.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Sodium bicarbonate, sodium chloride reports recording the termmedian drug in osmotic laxative
- Drug ineffectivethe medicine did not work as expected57.3%387
- Macular degenerationa disease of the central retina54.5%368
- Asthmaasthma43%290
- Headachehead pain37.5%253
- Dyspnoeashortness of breath33.8%228
- Wheezingwheezing30.7%207
- Chronic sinusitis29.3%198
- Nauseafeeling sick27.1%183
- Abdominal painstomach or belly pain26.1%176
- Constipationconstipation25.9%175
- Hypertensionhigh blood pressure25.5%172
- Malaisegeneral feeling of being unwell24.3%164
- Pyrexiafever24.1%163
- Weight decreasedweight loss23.7%160
- Off label useused for a purpose or in a way not on the label23.3%157
- Painpain, site not specified22.8%154
- Paraesthesia oral22.8%154
- Renal disorder22.8%154
- Gastrooesophageal reflux diseaseacid reflux22.5%152
- Infusion related reactiona reaction during or soon after an infusion20.9%141
- Dyspepsiaindigestion20.3%137
- Procedural painpain from a procedure20%135
- Anaemialow red blood cells19.6%132
- Colitisinflamed bowel19.6%132
- Erythemaskin redness19.6%132
- Female genital tract fistula19.6%132
- Frequent bowel movements19.4%131
Top 30 of 189 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 17 drugs in the osmotic laxative class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 129,514 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 0.9% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Rhinorrhoea | 30 | 4.4% |
| Rhinitis | 2 | 0.3% |
The indication field is filled in by the reporter and is often blank; shares are of all 675 reports.
In context
| Measure | Sodium bicarbonate, sodium chloride | Osmotic laxative | All reports |
|---|---|---|---|
| Reports as suspect product | 675 | 129,514 | 20,646,523 |
| Share of that pool | — | 0.5% | 0% |
| Reports, latest 12 months | 29 | — | 1,332,454 |
| Marked serious | 100% | 54.5% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 1 | 152 | 91 |
| Hospitalisation recorded, per 1,000 reports | 655 | 286 | 213 |
| Consumer-filed share | 27.9% | 61% | 45.8% |
| Top term, share of reports | Drug ineffective 57.3% | median 9.3% | 6.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the osmotic laxative class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| MiraLAX | brand | 38,188 | 1,721 | 7.2% |
| Extraneal | brand | 30,830 | 733 | 83.6% |
| Sodium chloride | generic | 11,044 | 1,389 | 92.5% |
| Delflex | brand | 8,765 | 676 | 53.8% |
| Potassium chloride | generic | 8,172 | 518 | 86.4% |
| DIANEAL PD-2 with Dextrose | brand | 7,178 | 161 | 88.6% |
| Polyethylene glycol 3350 | generic | 5,750 | 726 | 17.8% |
| Lactulose | generic | 4,133 | 353 | 87.1% |
| SUPREP Bowel Prep | brand | 3,664 | 35 | 9.1% |
| Sodium bicarbonate | generic | 3,342 | 308 | 92.1% |
| Dulcolax | brand | 2,893 | 137 | 63.8% |
| Sutab | brand | 1,513 | 151 | 12% |
| Bss | brand | 1,047 | 41 | 89.6% |
| DIANEAL Low Calcium with Dextrose | brand | 970 | 26 | 97.4% |
| Polyethylene glycol | generic | 760 | 58 | 85.5% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Sodium bicarbonate, sodium chloride reports
How many adverse event reports has FDA received for Sodium bicarbonate, sodium chloride?
675 reports list Sodium bicarbonate, sodium chloride as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 29 of them arrived in the latest 12 months. Another 258 list it only as a concomitant medication.
What reactions are recorded in Sodium bicarbonate, sodium chloride reports?
drug ineffective (57.3%), macular degeneration (54.5%), therapeutic product effect incomplete (47.3%), asthma (43%) and headache (37.5%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Sodium bicarbonate, sodium chloride was responsible.
How serious are the reports?
100% are marked serious by the reporter. Among the outcomes recorded, 0.1% of reports include death and 65.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (51%), consumer or non-health professional (27.9%) and physician (20.7%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Sodium bicarbonate, sodium chloride rising?
29 reports in the 12 months to June 2026, down 61% from 74 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Sodium bicarbonate, sodium chloride was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Sodium bicarbonate, sodium chloride?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Sodium bicarbonate, sodium chloride as a suspect or interacting product; reports listing it only as a concomitant medication (258) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.